Lite Strategy (LITS) vs Rockwell Medical (RMTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rockwell Medical (RMTI) has outperformed Lite Strategy (LITS) over the past year, losing 34.6% versus a loss of 52.8%. Over five years, RMTI leads with a -88.0% price change compared with -98.5% for LITS. Lite Strategy is the larger company by market cap ($24.0 million vs $23.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LITS | RMTI |
|---|---|---|
| Share price | $0.8026 | $5.82 |
| Market cap | $23.99M | $23.12M |
| 1-day change | -4.03% | -7.03% |
| YTD return | -39.20% | -29.88% |
| 1-year return | -52.79% | -34.61% |
| 5-year return | -98.46% | -87.98% |
| Forward P/E | — | 83.14 |
| EPS (TTM) | $-1.38 | $-1.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $69.26M |
| Revenue growth (YoY) | — | -31.76% |
| Net income (latest FY) | $-71.15M | $-5.31M |
| Gross margin | — | 16.89% |
| Operating margin | — | -6.77% |
| Net margin | — | -7.67% |
| 52-week high | $1.99 | $12.90 |
| 52-week low | $0.69 | $4.89 |
| Distance from 52-week high | -59.67% | -54.88% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +243.64% |
| Average volume | 524.33K | 25.91K |
| Shares outstanding | 29.88M | 3.97M |
| Employees | 5 | 157 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RMTI has outperformed LITS by 18.2 percentage points over the past year.
About Lite Strategy
LITS stock →Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Rockwell Medical
RMTI stock →Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
Health Care · Biotechnology: Pharmaceutical Preparations · 157 employees
LITS vs RMTI FAQ
Which is bigger, Lite Strategy or Rockwell Medical?
Lite Strategy (LITS) is larger, with a market capitalization of $23.99M compared with $23.12M for Rockwell Medical (RMTI).
Which stock has performed better over the past year, LITS or RMTI?
RMTI returned -34.61% over the past 12 months, compared with -52.79% for LITS (price return, excluding dividends). Past performance does not predict future results.
Are Lite Strategy and Rockwell Medical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.